DO NOT PASS THIS BY… MAJOR COLLABORATIVE STUDY FINDS ALL RISK AND NO BENEFIT – STUDY SHOWS 100% OF MYOCARDITIS IN KIDS IS FROM COVID19 SHOTS. MEANWHILE, EFFECTIVENESS DATA SHOW NO BENEFIT TO KIDS.
Study Links COVID-19 mRNA Shots, Not Infection to Heart Failure in Children. This MASSIVE study also shows no benefit in reduction of infection.
ACTION ITEM: CONTACT THE FDA AND DEMAND THEY PREVENT ALL CHILDREN FROM GETTING THESE INJECTIONS. LET THEM KNOW – ENOUGH IS ENOUGH.
A groundbreaking study by researchers from Oxford, Leeds, Harvard, and Bristol has confirmed that myocarditis and pericarditis only appear in children and adolescents following COVID-19 vaccination, not after infection. This extensive research analyzed official government data from over 1 million English children and adolescents, comparing vaccinated and unvaccinated subjects aged 5-11 and 12-15.
Key findings include:
All cases of myocarditis and pericarditis during the study period occurred in vaccinated individuals.
Most myocarditis and pericarditis cases were recorded after the first dose of the vaccine.
Hospitalizations related to COVID-19 were extremely rare among children and adolescents.
Over 50% of children who had myocarditis following the shot required hospitalization.
Read the full study here for more detailed insights. (See link for article, study, and to contact the FDA)
_______________
Remember that Aldén et al has been highly censored but critical to understand. Reverse transcription of mRNA, inserting the foreign code into human DNA has been one of the greatest fears during the mass, indiscriminate ‘vaccination’ campaign. Go here to watch Dr. Peter McCullough discuss how getting the Pfizer or Moderna COVID-19 shot may be permanent for the vaccinated and their progeny.
Prenatal Exposure to COVID-19 mRNA Vaccine BNT162b2 Induces Autism-Like Behaviors in Male Neonatal Rats: Insights into WNT and BDNF Signaling Perturbations
Prenatal Exposure to COVID-19 mRNA Vaccine BNT162b2 Induces Autism-Like Behaviors in Male Neonatal Rats: Insights into WNT and BDNF Signaling Perturbations
The COVID-19 pandemic catalyzed the swift development and distribution of mRNA vaccines, including BNT162b2, to address the disease. Concerns have arisen about the potential neurodevelopmental implications of these vaccines, especially in susceptible groups such as pregnant women and their offspring. This study aimed to investigate the gene expression of WNT, brain-derived neurotrophic factor (BDNF) levels, specific cytokines, m-TOR expression, neuropathology, and autism-related neurobehavioral outcomes in a rat model. Pregnant rats received the COVID-19 mRNA BNT162b2 vaccine during gestation. Subsequent evaluations on male and female offspring included autism-like behaviors, neuronal counts, and motor performance. Molecular techniques were applied to quantify WNT and m-TOR gene expressions, BDNF levels, and specific cytokines in brain tissue samples. The findings were then contextualized within the extant literature to identify potential mechanisms. Our findings reveal that the mRNA BNT162b2 vaccine significantly alters WNT gene expression and BDNF levels in both male and female rats, suggesting a profound impact on key neurodevelopmental pathways. Notably, male rats exhibited pronounced autism-like behaviors, characterized by a marked reduction in social interaction and repetitive patterns of behavior. Furthermore, there was a substantial decrease in neuronal counts in critical brain regions, indicating potential neurodegeneration or altered neurodevelopment. Male rats also demonstrated impaired motor performance, evidenced by reduced coordination and agility. Our research provides insights into the effects of the COVID-19 mRNA BNT162b2 vaccine on WNT gene expression, BDNF levels, and certain neurodevelopmental markers in a rat model. More extensive studies are needed to confirm these observations in humans and to explore the exact mechanisms. A comprehensive understanding of the risks and rewards of COVID-19 vaccination, especially during pregnancy, remains essential.
Dr. Kenneth Liegner is a Board Certified Internist with additional training in Pathology and Critical Care Medicine, practicing in Pawling, New York. He has been actively involved in diagnosis and treatment of Lyme disease and related disorders since 1988.
He has published articles on Lyme disease in peer-reviewed scientific journals and has presented poster abstracts and talks at national and international conferences on Lyme disease and other tick-borne diseases. He has cared for many persons seriously ill with chronic and neurologic Lyme disease. His work has focused on the serious morbidity and (occasional) mortality that can eventuate from this aspect of the illness. He has emphasized the urgent need for widespread clinical availability of improved methods of diagnostic testing and for development of improved methods of treatment for Lyme disease in all its stages. He holds the first United States patent issued proposing application of acaricide to deer for area-wide control of deer-tick populations as a means of reducing the incidence of Lyme disease. He has authored In the Crucible of Chronic Lyme Disease – Collected Writings & Associated Materials, a documentational history of the struggle to characterize the nature of Lyme disease in the late 20th and early 21st centuries, published November 2015.
He served two terms on the Board of Directors of the International Lyme and Associated Diseases Society (ILADS), is on the Scientific Advisory Board of the Lyme Disease Association, Inc, and is on the Medical Advisory Board of the Global Lyme Alliance. He is a member of The American Association of Physicians and Surgeons.
He was the first physician to apply disulfiram in the treatment of Lyme disease and published his experience with his first three patients in the peer-reviewed journal Antibiotics, May 2019.
This May Awareness Guest Blog delves into the intricacies of Lyme disease with Kenneth Liegner, MD, a Board Certified Internist with specialized training in Pathology and Critical Care Medicine. In this interview, Dr. Liegner shares his journey into the world of Lyme disease, its evolving treatment, and his ongoing efforts to improve diagnostic methods and therapeutic solutions. He discusses the critical role of thinking holistically, patient advocacy, and the importance of organizations such as the Lyme Disease Association, Inc. in raising awareness and funding research. Dr. Liegner offers valuable insights and reflections on tackling one of the most challenging and misunderstood diseases of our time.
An Interview with Kenneth Liegner, MD
1. How did you get interested in specializing in Lyme and tick-borne diseases?
I started a solo private office-based practice of internal medicine in Armonk, NY with some critical care at the local hospital (Northern Westchester Hospital, Mt. Kisco, NY) around 1985. Unbeknownst to me at the time, northern Westchester was becoming a ‘hot-bed’ of Lyme disease and some of the earliest cases of Lyme meningitis were diagnosed there. I knew virtually nothing about Lyme disease at the time, other than the name and the story of its discovery by Allen Steere in Lyme, CT. Then I began seeing cases of the illness, which, really no clinician in Westchester could avoid. I found them extremely puzzling and challenging. They didn’t behave the way they were supposed to! Symptoms would keep coming back despite application of ‘recommended’ antibiotic treatments. Gradually, through trial and error, I found it was necessary to extend the duration of treatment: first doubled, then later on tripled, quadrupled and finally, for some, adopted a somewhat ‘open-ended’ (not necessarily never-ending) approach. In the early 1990s, there was a very convivial and collaborative approach between clinicians and academicians and everyone was excited to be learning about this new disease.
Things changed dramatically with the 1995 Dearborn conference and the roll-out of the Lyme vaccine, LYMErix, following which a very rigid ‘construct’ of Lyme disease was promoted as dogma. This had not previously been the case. Care for persons with Lyme disease was a ‘niche’ needing to be filled, and I filled it. My background in critical care (and anatomic pathology) was very suitable for grappling with a multi-system illness that required thinking holistically about the entire organism/person and not just isolated ‘organ systems’ into which many of the sub-specialties and sub-specialists in medicine were ‘siloed’. I was fortunate to be able to collaborate with many of the finest researchers in both academia and at CDC & NIH resulting in publication of some important abstracts and papers. This was very gratifying and intellectually stimulating. There was a sense of community and shared effort at the time.
2. What do you see as the biggest difference(s) from when you began focusing on Lyme and where we are today?
I started practice towards the end of the so-called ‘Golden Age’ of Medicine. A time when private practice was prevalent, physicians worked for the patient and the Hippocratic Oath was revered. Paul Starr accurately predicted the ‘coming of the corporation’ in his excellent book, The Social Transformation of American Medicine. The advent of the hospitalist system also dramatically changed the nature of hospital medicine, where primary physicians no longer followed their patients in the hospital, guiding their care, watching out for their best interests and arranging optimal consultations. This served insurance company and hospital CEO corporate interests, enabling ‘efficiencies’ of care and a higher throughput, but completely broached often decades-long doctor-patient relationships. Hierarchical structures in hospital systems, including Pharmacy & Therapeutics Committees, helps explain why it remains, to this day, so difficult for persons with Lyme and tick-borne diseases to get personalized care within the hospital setting as well as within vertically-integrated corporate healthcare settings.
3. What are you most excited about in today’s treatment and/or hope for Lyme and other tick-borne diseases?
There is growing awareness of the complexity of tick- and vector-borne diseases. Meticulous scientific studies at the bench-level, with animal studies and also in clinical reports, elucidate a range of mechanisms that may be operative in maintaining illness. This raises consideration of novel interventions to improve people’s quality of life, which is paramount. Stalwart efforts by the patient community has resulted in government recognition that far greater financial and scientific resources are needed in this field. Recalcitrant refusal to acknowledge the important role of persistent borrelial infection despite prior application of antibiotic treatment is frustrating and impedes progress in devising solutions. Despite some improved funding, a much greater level is needed.
4. Why is it important for LDA and other nonprofits to increase awareness for Lyme disease and other tick-borne illnesses?
Many medical, scientific, and societal problems vie for attention and compete for government resources. The voice of patients expressed individually and through patient advocacy and educational organizations to their legislative representatives at local, state, and national levels is extremely important. Due to limited government resources, not all investigators are able to secure grants or funding even when their work is highly meritorious. There remains an important role for private funding of research.
5. Please share any past reflections or your experiences with the LDA. . .
The LDA has held annual scientific conferences of high quality for decades. Collaborations with academicians, various branches of the Federal and State governments as well as clinicians has raised awareness of and respect for concerns of patients and the public. LDA’s financial support of scientific research has enabled innumerable published peer-reviewed articles listed on PubMed, advancing medical knowledge, ultimately improving patient care. The volunteered efforts of Pat Smith and the support staff of the LDA and its affiliates represent the highest embodiment of ideals of service.
WHEELCHAIR-BOUND CEO REGAINS ABILITY TO WALK AFTER LYME DISEASE TREATMENT
Lyme arthritis is characterized by joint swelling lasting for weeks to months and potentially causing permanent joint damage. It can worsen symptoms in patients with existing joint conditions such as osteoarthritis and may go undiagnosed, leading to unnecessary surgeries.
In this case report, “Exacerbation of Osteoarthritic Joint Pain by Lyme Disease,” Bennani and colleagues demonstrate the importance in identifying an underlying tick-borne infection, as appropriate treatment can dramatically improve a patient’s quality of life.¹
A 63-year-old man, who was wheelchair-bound, presented to his clinician’s office with severe pain in both knees, which had been progressively worsening over several months. He had previously undergone bilateral knee arthroscopies for meniscal tears and recently received corticosteroid injections, which did not alleviate his pain.
The authors suggest that while corticosteroids can reduce inflammation and alleviate pain, the bacterial infection can continue to proliferate and destroy knee tissue.
“Before treatment, our patient was wheelchair-bound due to the combination of existing osteoarthritis and the manifestation of Lyme disease in his knees.”
“The patient did report that he was recently on erythromycin for an upper respiratory infection (URI) and indicated that his knees felt better while he was taking erythromycin,” the authors state.
Furthermore, the patient, who worked as a chief executive officer (CEO) of a company, was an avid hunter and reported that his dog had Lyme disease.
Given that the patient’s dog had Lyme disease, Lyme IgG and Lyme IgM studies were ordered.
Testing for Lyme disease was positive and the patient began treatment with doxycycline.
“Upon completion of doxycycline therapy, our patient noted significant improvement in his knee pain,” the authors state.
His improvement was so significant that the patient no longer needed the use of a wheelchair and was able to cancel his bilateral knee replacement surgery.
Authors conclude:
“Our patient was able to avoid a costly, high-risk surgical procedure with the detection and treatment of his Lyme disease.”
“Lyme disease should always be a consideration in the differential diagnosis of patients who have lived or have traveled to areas that are endemic to the disease and who tend to have outdoor lifestyles.”
Bennani A Z, Chegwidden B, Lambroussis C G, et al. (April 29, 2024) Exacerbation of Osteoarthritic Joint Pain by Lyme Disease. Cureus 16(4): e59318. doi:10.7759/cureus.59318
_______________
**Comment**
The first thing my mind said to this was duh! Of course the man felt extremely better when being on erythromycin! But, alas, this is where we are in 2024 – after 40 years of mythology about tick-borne illness.
Nothing’s changed.
If you want real help, you must go outside the mainstream medicine (MSM) paradigm, and get to a Lyme literate doctor (LLMD) even though MSM still calls them quacks.
A few important points:
He’s an avid hunter and is outside. This raises the risk for tick-borne infections but you can still get infected in your own backyard.
His dog has Lyme. This happened in our family as well. Dogs are sentinels and a warning shot over the bow. Testing for animals appears to be much better than for people and if your pet is infected – be on guard. Estimates for Lyme based on canine models and human seroprevalence data is far higher than ‘official’ data.
While corticosteroids are loved by doctors for reducing inflammation and pain, they are a double-edged sword for patients who are infected. Since they dampen the immune system they allow infections to worsen which is why identifying underlying infections is imperative.
I’m sorry but by NOW, if a patient improves while on antibiotics, the FIRST thing they should consider is tick-borne infections. I mean really, this nonsense has gone on for far too long.
This man was lucky in that he tested positive. What about the sorry suckers who don’t? I’ll tell you what happens – they are kicked to the curb and allowed to languish for years and years and years until their lives are destroyed and it kills them. Not a very happy ending but it’s happening to thousands upon thousands.
Notice the miraculous turn around of this patient. This often happens – but sometimes it doesn’t because the WRONG treatment is used and it’s a different pathogen to blame. There is nuance to treating this and MSM is woefully uneducated and unprepared. Run away from MSM as fast as you can and get to someone who knows what they are doing. I’m serious. Don’t mess around with this. You will thank me later.
Honoring Lyme Disease Awareness Month with a Multi-Year Plan to Change the Lyme Disease Status Quo
By: Daniel Desautels PhD, Health Scientist, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Deanna Lebel MHS, ORISE Fellow, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services and Kristen Honey PhD, PMP, Chief Data Scientist, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services
Summary:
HHS addressing serious national threats of Lyme disease and other tickborne illnesses
The Multi-Year Plan includes five years of HHS Lyme Innovation goals, impacts to date, and future activities to move the needle on Lyme disease and tickborne diseases with Lyme disease patients at the core of the HHS innovation process. Launched in 2018, the HHS Lyme Innovation initiative harnesses the power of collaboration, data-driven innovation, and emerging technologies to address the serious threats of Lyme disease and other tickborne illnesses.
Lyme disease is the most common vector-borne disease in the United States with approximately 63,000 cases reported to the Centers for Disease Control and Prevention in 2022. But reported cases tell only a portion of the story: CDC estimates approximately 476,000 people are diagnosed with Lyme disease in the United States each year. Due to shifting land use patterns, global travel and trade, and a changing climate, the threat of existing and emerging tickborne diseases continues to grow.
“The HHS Lyme Innovation initiative has made groundbreaking progress accelerating patient-informed innovations for diagnostics, treatment, and care,” said Acting Deputy Assistant Secretary for Science and Medicine, Leith J. States, MD, MPH, MBA, FACPM. As described in the Multi-Year Plan, HHS Lyme Innovation is a broad umbrella of methods with innovation and partnership activities.
On-going efforts will continue advancing Lyme disease diagnostics, open data for Lyme Innovation, human-centered design for Lyme Innovation, and scientific understanding of Lyme infection-associated chronic illnesses .
The Multi-Year Plan aligns with the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People – PDF (Vector-Borne Disease National Strategy), published earlier this year. The first interagency effort of its kind, the Vector-Borne Disease National Strategy identifies and describes federal priorities to detect, prevent, respond to, and control diseases and conditions caused by vectors in the United States.
HHS and CDC are leading execution of the strategy in consultation with agencies across the federal government. Successful implementation of the Vector-Borne Disease National Strategy depends on strong collaboration within the government and with external partners. On May 23, 2024, HHS will present updates on the Vector-Borne Disease National Strategy via livestream at https://www.hhs.gov/live/index.html.
Moving the needle on Lyme disease will require continued collaboration, support, leadership, and excellence in innovation and implementation. Collaboration within and outside of the federal government is necessary to protect the nation and save lives. Government transparency is a priority for the HHS Lyme Innovation Initiative, which rests on a foundation of open science, open data, and open innovation.
______________
**Comment**
Don’t expect anything helpful to come out of this. A lot of money will be appropriated, the same crappy science will be done, and the same pockets will be lined.
In a recent meta-analysis1,2 posted on preprints.org, Japanese researchers warn of potentially deadly risks to patients who receive blood from people who have taken mRNA covid injections and call for urgent action to ensure the safety of the global blood supply. According to the authors:3
… many countries around the world have reported that so-called genetic vaccines, such as those using modified mRNA encoding the spike protein and lipid nanoparticles as the drug delivery system, have resulted in post-vaccination thrombosis and subsequent cardiovascular damage, as well as a wide variety of diseases involving all organs and systems, including the nervous system …
[B]ased on these circumstances and the volume of evidence that has recently come to light, we call the attention of medical professionals to the various risks associated with blood transfusions using blood products derived from people who have suffered from long covid and from genetic vaccine recipients, including those who have received mRNA vaccines, and we make proposals regarding specific tests, testing methods, and regulations to deal with these risks.
Blood From Injected Donors May Pose Risk to Neurological Health
One particular risk addressed in this paper is the implications of blood tainted with prion-like structures found within the spike protein. Prions are misfolded proteins that can cause neurodegenerative diseases, such as Creutzfeldt-Jakob Disease (“CJD”) in humans, by inducing the misfolding of normal proteins in the brain.
Prion diseases are characterised by a long incubation period, followed by rapid progression and high mortality. The suggestion that the spike protein of SARS-CoV-2, especially from certain variants, might contain prion-like domains raises concerns for several reasons:
Transmission risk – If spike proteins with prion-like structures can be transmitted through blood transfusions, there might be a risk of inducing prion diseases in recipients. Prion diseases are notoriously difficult to diagnose early, have no cure and are fatal, making any potential transmission through blood products a significant safety concern.
Detection and removal challenges – Current blood screening processes do not specifically test for prions, partly because prion diseases are rare and partly due to the technical challenges in detecting prions at low concentrations. If spike proteins with prion-like properties are present in the blood of covid injected people, existing blood safety protocols may not be adequate to prevent transmission.
Long-term safety concerns – Prion diseases have long latency periods, meaning that symptoms can appear years or even decades after exposure. This delay complicates efforts to trace the source of an infection back to a blood transfusion and assess the safety of blood supplies over time.
Impacts on blood supply management – Concerns about the potential risks associated with prion-like structures in spike proteins might lead to changes in donor eligibility criteria or the implementation of additional screening measures. These changes could impact the availability of blood products, which are critical for routine medical procedures.
Public confidence – Public awareness of these potential risks, even if they are theoretical or have a very low likelihood of occurring, could affect people’s willingness to donate or receive blood transfusions, thereby lowering blood donation rates and the overall trust in the safety of blood transfusions.
The authors stress the need for comprehensive studies to better understand the implications of these prion-like structures in the spike protein, not only for mRNA jab safety but also for the broader implications for public health measures like blood transfusion practices.
Other Potential Health Hazards of Contaminated Blood
Contaminated blood may also pose other serious health risks, including:
1. Reduced immune function among blood recipients – It’s been shown that the more doses of the covid “vaccine” you’ve received, the more likely you are to suffer future infections, either by SARS-CoV-2 or other viruses, due to antibody-dependent enhancement.
Blood donations from people who have received several doses of mRNA injections may not provide adequate immunity against common infections, resulting in subclinical infections and diseases in recipients.
2. Formation of blood clots and amyloid aggregates – If the immune system of a blood recipient isn’t strong enough to neutralise spike protein, blood clots and amyloid aggregates may also form.
3. Chronic inflammation – Prolonged exposure to the antigens from the covid-19 injections can trigger the generation of IgG4 antibodies, resulting in chronic inflammation and immune dysfunction.
IgG4 antibodies are often associated with chronic exposure to antigens, such as those seen in persistent infections, certain cancers, and prolonged exposure to allergens. IgG4 antibodies are also associated with a unique condition known as IgG4-Related Disease (IgG4-RD), a fibro-inflammatory condition characterised by swellings or masses in affected organs.4
Blood Transfusions and the Risk of Autoimmune Diseases
The authors also raise concerns about the potential of contaminated blood to cause autoimmune diseases in recipients. Recent research found that the RNA pseudouridylation, a process in which uracil is swapped out for synthetic methylpseudouridine, can cause frameshifting, basically a glitch in the decoding, which can trigger the production of off-target aberrant proteins.
The antibodies that develop as a result may, in turn, trigger off-target immune reactions. In addition to that, lipid nanoparticles (“LNPs”), a key component of the covid injections, have been identified as highly inflammatory and possessing more potent adjuvant activity compared to traditional vaccine adjuvants, which further increases the risk of an autoimmune response. As reported in the featured paper:5
Recent studies have shown that RNA pseudouridylation can result in frameshifting. It is not yet clear whether a portion of the pseudouridinated mRNA for the spike protein is translated into another protein of unknown function in vaccine recipients. If these proteins are also pathogenic, additional testing for such frameshift proteins may be needed in the future.
Even if a frameshift protein is not toxic, it must be foreign to the body and could cause autoimmune disease. In addition, LNPs themselves are highly inflammatory substances … LNPs have been found to have stronger adjuvant activity than the adjuvants used in conventional vaccines, and there is also concern about autoimmune diseases resulting from this aspect.
Thus, although it is not clear what the causative agent of autoimmune disease is, the large number of reported cases of autoimmune disease following genetic vaccination is extremely concerning.
The very mechanism of gene vaccines that causes one’s own cells to produce the antigens of pathogens carries the risk of inducing autoimmune diseases, which cannot be completely avoided even if mRNA pseudouridylation technology is used.
In this context, individuals with a positive blood test for spike protein may need to have interviews and additional tests for autoimmune disease indicators, such as antinuclear antibodies.
Alternatively, if the amino acid sequence of the protein resulting from the frameshift is predictable, these candidate proteins could be included in the initial mass spectrometry assay. In any case, it is particularly important to develop tests and establish medical care settings in anticipation of these situations.
Proposals for Managing Blood Collection
The authors outline several specific proposals for managing blood collection and blood products from individuals who have received genetic “vaccines.” Given the variety of blood-related abnormalities observed post-injection, the researchers argue that rigorous and precautionary measures in blood handling and transfusion practices have now become a necessity.
A key part of the proposal involves conducting thorough interviews with potential blood donors. These interviews should cover their vaccination status, number of doses received, their covid-19 infection history, and any symptoms they might be experiencing that could indicate conditions like post-vaccination syndrome (“PVS”), long covid or other complications.
The researchers also recommend deferral periods for blood collected from covid injection recipients – 48 hours for mRNA shots and six weeks for AstraZeneca DNA jab recipients. A series of tests are also proposed to ensure the safety of collected blood, including:
Mass spectrometry to measure spike protein content
PCR for detecting the presence of spike protein mRNA and DNA
Testing for markers associated with autoimmune disorders
Enzyme-linked immunosorbent assay (ELISA)
Immunophenotyping
Liquid biopsies combined with proteomics to detect and quantify spike protein and its mRNA
The authors also note that policies and procedures must be constantly revised as new risks and problems with blood products derived from mRNA and DNA injection recipients are identified.
Ensuring Safety of Current Blood Products
The paper also reviews strategies to ensure the safety of blood products already collected, highlighting the complex challenges that medical institutions, regulatory bodies, and the broader healthcare ecosystem must navigate in the wake of the widespread use of mRNA injections.
The primary concern is the risk posed to patients by the use of blood products from donors who have received gene-based injections without confirming the presence or absence of spike proteins or modified mRNA. To ensure their safety, methods to quantify potential contaminants must be developed and implemented as soon as possible.
Another critical issue that must be addressed is the current lack of reliable methods to remove spike proteins or modified mRNA from blood products. The authors warn that, given the potential persistence, low solubility, heat resistance and radiation resistance of these components, current methodologies are inadequate for the job. The only solution, they say, is to discard all blood products found to contain these contaminants until effective removal techniques are established.
Researchers Call for Widespread Blood Testing
Additionally, the researchers call for widespread testing of both injected and non-injected to assess the potential transmission of spike proteins through exosomes (so-called shedding).
As noted by the authors:
… when exosomes collected from vaccine recipients were administered to mice that had not been vaccinated with the genetic vaccine, the spike protein was transmitted.
Therefore, it cannot be denied that the spike protein and its modified genes can be transmitted through exosomes. For this reason, we suggest that full testing be done initially, regardless of genetic vaccination status, and that a cohort study be conducted to quickly capture the full picture …
In addition … it cannot be ruled out that even those who have not been vaccinated with the genetic vaccine, but have had long covid, may have residual spike proteins or fibrin-derived microthrombi in their bodies, so it would be advisable to conduct the same testing and follow-up as for genetic vaccine recipients.
The presence or absence and amount of anti-nucleocapsid antibodies as well as antibody isotypes may be an indicator(s) in distinguishing whether genetic vaccination or long covid is the cause. In any case, these cohort studies are expected to help establish cutoff values for blood levels of spike protein and other substances to determine the safety of blood products.
Faksova et al. conducted a large cohort study of 99 million people using a multinational Global Vaccine Data NetworkTM (GVDN®) and found a significantly increased risk of myocarditis, pericarditis, Guillain-Barre syndrome and cerebral venous sinus thrombosis in genetic vaccine recipients.
Ensuring the traceability of blood products and establishing a rigorous legal and regulatory framework to manage the myriad issues arising from the use of blood products derived from covid-injected individuals are also paramount. This includes creating systems for the registration of all potential donors, ensuring the traceability of blood products and conducting recipient outcome studies.
Call to Pause: Evaluating the Risks and Benefits of Genetic Vaccines for a Safer Future
In conclusion, the authors point out that if we continue using mRNA-LPN-based platforms to replace conventional vaccines or create new ones, then the risks to our blood and bone marrow supply will be augmented further.
“The impact of these genetic vaccines on blood products and the actual damage caused by them are unknown at present,” they write.6
Therefore, in order to avoid these risks and prevent further expansion of blood contamination and complication of the situation, we strongly request that the vaccination campaign using genetic vaccines be suspendedand that a harm-benefit assessment be carried out as early as possible, as called for by Fraiman et al.7 and Polykretis et al.8
T]he health injuries caused by genetic vaccination are already extremely serious, and it is high time that countries and relevant organisations take concrete steps together to identify the risks and to control and resolve them.
Dr. Joseph Mercola is the founder and owner of Mercola.com, a Board-Certified Family Medicine Osteopathic Physician, a Fellow of the American College of Nutrition and a New York Times bestselling author. He publishes multiple articles a day covering a wide range of topics on his website Mercola.com.
_______________
Japan Ahead of the Curve
Japan appears to be ahead of the curve not only in showing the seriousness of the mRNA injection issues, but politically as well. Recently, Kazuhiro Haraguichi, former Japanese Minister for Internal Affairs has become the first major politician to apologize to the unvaccinated for the tsunami of deaths occurring among the ‘vaccinated.’ After getting two out of three COVID shots which were from ‘lethal’ batches, he developed a rapidly progressing form of cancer. Three of his colleagues were also severely affected, but they haven’t spoken out. He states those that do are censored. He has urged people to stand united in challenging the government.
Thelibertybeacon.com reports: One of the key points in Haraguchi’s speech was his criticism of the ban on Ivermectin, a drug developed by Dr. Satoshi Omura, which he believed could have played a significant role in combating the pandemic. Haraguchi questioned the motives behind the ban, suggesting that economic interests were prioritized over public health.
Madison Area Lyme Support Group 